A first-of-its-kind drug for hepatitis B is allowing some patients to stop treatment without showing signs of the dangerous liver virus, in what is called a “functional cure”, researchers reported on Thursday.In two international studies, about one in five patients given the experimental drug saw their virus reduced to levels low enough for the immune system to keep it in check.

Researchers reported Thursday that in two international studies, about 1 in 5 patients given the experimental drug for six months saw their virus reduced to levels low enough that…

WASHINGTON (AP) – A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the dangerous liver virus, what's called a "functional…

La mayoría de las personas se recupera de la infección, pero esta representa grandes riesgos para quienes no lo hacen; un fármaco experimental podría ser una solución para el 20%…

In an editorial published in the New England Journal of Medicine, University of Michigan Health hepatologist Anna S. Lok, M.D., hails newly announced results of the B-Well…

Across two large trials, roughly 20% of people treated with bepirovirsen had undetectable levels of the virus after stopping all treatment.

A first-of-its-kind drug for hepatitis B is allowing some patients to stop treatment without showing signs of the dangerous liver virus, in what is called a “functional cure”,…